Micromet's BiTE(R) Antibodies Reveal Unique Mode... (g phase 1 study isconsistent with the co...)

HOME >> MEDICINE >> NEWS

Micromet's BiTE(R) Antibodies Reveal Unique Mode of Action

Date:11/6/2007

g phase 1 study is consistent with the conditional T cell activation observed in the newly published studies."

References

1 Brischwein K, Parr L, Pflanz S et al. Strictly target cell-dependent

activation of T cells by bispecific single-chain antibody constructs of

the BiTE class. J Immunother. Vol. 30 (8):798-807, November/December

2007.

2 Brandl C, Hass C, d'Argouges S et al. The effect of dexamethasone on

polyclonal T cell activation and redirected target cell lysis as induced

by a CD19/CD3-bispecific single-chain antibody construct. Cancer Immunol

Immunother. Vol. 56:1551-1563 (2007).

About BiTE(R) Antibodies

BiTE(R) antibodies are designed to direct the body's cytotoxic, or cell- destroying, T cells against tumor cells, and represent a new therapeutic approach to cancer therapy. BiTE antibodies have been shown to induce an immunological synapse between a T cell and a tumor cell in the same manner as observed during physiological T cell attacks. These cytolytic synapses enable the delivery of cytotoxic proteins from T cells into tumor cells, ultimately inducing a self-destruction process in the tumor cell referred to as apoptosis, or programmed cell death. In the presence of BiTE antibodies, T cells have been demonstrated to serially eliminate tumor cells, which explains the activity of BiTE antibodies at very low concentrations and at very low ratios of T cells to target cells. Through the process of killing cancer cells, T cells proliferate, which leads to an increased number of T cells at the site of attack.

Several antibodies in Micromet's product pipeline are BiTE antibodies and have been generated based on Micromet's proprietary BiTE product development platform. The most advanced BiTE antibody is MT103 (MEDI-538), targeting CD19, and has provided proof-of-concept in an ongoing phase 1 clinical study in advanced non-Hodgkin's lymphoma patients. Three other BiTE antibodies,
'/>"/>

0

GOOD

Page: 1 2 3 4 5
Related medicine news :

1. Scripps Research scientists shed new light on how antibodies fight HIV
2. Brain imaging reveals breakdown of normal emotional processing
3. Survey reveals disparities in skin cancer knowledge, protection among high school students
4. Large intensive care study reveals vital recommendations for treatment of brain injury patients
5. Just Completed Studies Reveal Impact of New Medicare Reimbursement Regulations
6. Inc. Magazine Reveals Its 26th Annual List of Americas 500 Fastest-Growing Private Companies
7. Survey From The Partnership and MetLife Foundation Reveals Important Role Todays Grandparents Play in Teens Lives
8. Trade-offs reveal no clear favorites in alternative energy market
9. Revealing the workings of Mother Natures blowtorch
10. Scientists reveal DNA-enzyme interaction with first ever real time footage
11. New Survey Reveals Kidney Patients Concern About Medicare Policies

Post Your Comments:

Micromet's BiTE(R) Antibodies Reveal Unique Mode...(g phase 1 study isconsistent with the co...),Health